DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effects of Tegaserod Vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Constipation and Dyspepsia

Intervention: Tegaserod and Placebo (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: Novartis

Official(s) and/or principal investigator(s):
Nicholas Talley, MD, Principal Investigator, Affiliation: Mayo Clinic
Michael Crowell, PhD, Principal Investigator, Affiliation: Mayo Clinic

Summary

To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia

Clinical Details

Official title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Tegaserod (6 Mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: To determine the effect of one week of tegaserod on the passage of content through the gut by radiological procedures.

Secondary outcome:

To evaluate the PD effects of tegaserod on upper & lower GI transit

To evaluate global well-being & upper and lower GI symptoms in daily assessment of bowel habits and weekly global and individual symptom assessments

Eligibility

Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Females aged 18 to 64 years of age

- Patients must present with two or more of the following criteria for chronic

constipation for at least 12 weeks prior to entering the study: 1. Less than 3 bowel movements per week 2. Hard or lumpy stools 3. Straining during bowel movements 4. Feeling of incomplete evacuation

- Patients must report overlapping symptoms consistent with dyspepsia, such as

mid-upper abdominal discomfort characterized by early satiety, post-meal fullness and bloating Exclusion Criteria:

- Patients with a recent history of, or current frequency of diarrhea occuring more

than once per month off of laxatives

- Clinically significant diagnosis of pelvic outlet obstruction or pelvic floor

dyssenergia as determined by the study physicians

- Patients with constipation secondary to medication use as determined by the study

physician

- Patients with clinically significant abnormal TSH levels at screening

- Patients that have heartburn or abdominal pain as their predominant GI symptom

- Evidence of cathartic colon or a history of laxative abuse

- Other protocol-defined inclusion/exclusion criteria may apply

Locations and Contacts

Additional Information


Last updated: September 7, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017